Etrade Capital Management Has Lowered Its Ptc (PTC) Stake; Last Week Antares Pharma, Inc. (ATRS) Analysts

March 17, 2018 - By Michael Collier

Etrade Capital Management Llc decreased Ptc Inc (PTC) stake by 51.18% reported in 2017Q3 SEC filing. Etrade Capital Management Llc sold 11,772 shares as Ptc Inc (PTC)’s stock rose 1.36%. The Etrade Capital Management Llc holds 11,229 shares with $632,000 value, down from 23,001 last quarter. Ptc Inc now has $9.35 billion valuation. The stock increased 0.26% or $0.21 during the last trading session, reaching $80.38. About 969,750 shares traded or 6.50% up from the average. PTC Inc. (NASDAQ:PTC) has risen 57.23% since March 17, 2017 and is uptrending. It has outperformed by 40.53% the S&P500.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 12 analyst reports since March 9, 2016 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Wednesday, March 14 report. The firm has “Buy” rating given on Tuesday, October 10 by Jefferies. H.C. Wainwright maintained Antares Pharma, Inc. (NASDAQ:ATRS) rating on Wednesday, November 8. H.C. Wainwright has “Buy” rating and $3.5 target. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Buy” rating by H.C. Wainwright on Friday, June 23. H.C. Wainwright initiated it with “Buy” rating and $5.0 target in Friday, September 8 report. The firm has “Buy” rating given on Monday, October 23 by H.C. Wainwright. Jefferies maintained Antares Pharma, Inc. (NASDAQ:ATRS) on Monday, August 7 with “Buy” rating. The company was maintained on Thursday, February 15 by H.C. Wainwright. The firm has “Buy” rating given on Monday, October 23 by Piper Jaffray. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Buy” rating by Jefferies on Wednesday, March 9. See Antares Pharma, Inc. (NASDAQ:ATRS) latest ratings:

14/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
15/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain

Investors sentiment decreased to 1.16 in 2017 Q3. Its down 0.13, from 1.29 in 2017Q2. It worsened, as 11 investors sold Antares Pharma, Inc. shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.56 million shares or 0.15% less from 53.64 million shares in 2017Q2 were reported. Manufacturers Life Ins The owns 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 119,903 shares. Moreover, Perkins Capital Mngmt has 1.24% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Alliancebernstein Ltd Partnership owns 36,900 shares. Raymond James, Florida-based fund reported 133,900 shares. Invesco Limited holds 0% or 49,914 shares in its portfolio. Citigroup reported 452 shares. Ballentine Ptnrs Limited Liability holds 0.02% or 100,000 shares in its portfolio. Legal & General Group Public Ltd reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Barclays Public Limited Company has 136,338 shares. Broadfin Capital Ltd Limited Liability Company invested in 3.21M shares. Wells Fargo Mn invested in 0% or 1.34 million shares. Guggenheim Capital Ltd, Illinois-based fund reported 408,944 shares. Janney Montgomery Scott Limited Company owns 10,000 shares. Citadel Advsrs Ltd Liability Corporation owns 114,848 shares. Moreover, Fmr Ltd Liability has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 2.91M shares.

Since October 3, 2017, it had 0 insider buys, and 2 selling transactions for $1.04 million activity. JACOB LEONARD S also sold $931,920 worth of Antares Pharma, Inc. (NASDAQ:ATRS) shares. GARRITY THOMAS J sold $105,000 worth of stock.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $380.72 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

The stock decreased 2.02% or $0.05 during the last trading session, reaching $2.43. About 1.56 million shares traded or 19.42% up from the average. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 207.14% since March 17, 2017 and is uptrending. It has outperformed by 190.44% the S&P500.

Investors sentiment increased to 1.07 in Q3 2017. Its up 0.01, from 1.06 in 2017Q2. It improved, as 39 investors sold PTC shares while 101 reduced holdings. 42 funds opened positions while 107 raised stakes. 87.30 million shares or 4.23% more from 83.76 million shares in 2017Q2 were reported. Castleark Mgmt Ltd Liability Corp has invested 0.14% in PTC Inc. (NASDAQ:PTC). Acadian Asset Management Ltd Liability has 1,172 shares for 0% of their portfolio. Ameritas Investment has invested 0.09% of its portfolio in PTC Inc. (NASDAQ:PTC). Nuveen Asset Mgmt Ltd Liability Corp reported 226,834 shares or 0.08% of all its holdings. 49,020 were reported by Franklin Resource Inc. Registered Advisor invested in 7,608 shares or 0.21% of the stock. Mai Management invested in 4,141 shares. 1832 Asset Mngmt Ltd Partnership has invested 0.01% in PTC Inc. (NASDAQ:PTC). Oregon Pub Employees Retirement Fund stated it has 0.04% of its portfolio in PTC Inc. (NASDAQ:PTC). Sumitomo Life Insurance holds 0.17% of its portfolio in PTC Inc. (NASDAQ:PTC) for 23,695 shares. Oppenheimer Asset Mngmt, a New York-based fund reported 1,634 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 68,572 shares. Guggenheim Ltd Company has 0% invested in PTC Inc. (NASDAQ:PTC). Commonwealth Of Pennsylvania School Empls Retrmt System invested in 0.01% or 16,865 shares. Jpmorgan Chase And invested in 0% or 3,124 shares.

Etrade Capital Management Llc increased Stanley Black & Decker Inc (NYSE:SWK) stake by 2,990 shares to 10,623 valued at $1.60M in 2017Q3. It also upped Citigroup Inc (NYSE:C) stake by 4,212 shares and now owns 22,960 shares. Public Storage (NYSE:PSA) was raised too.